Citi raised the firm’s price target on Bristol Myers (BMY) to $48 from $47 and keeps a Neutral rating on the shares. The firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of a Q3 earnings preview. The group is well positioned into the second half of 2025 and 2026 as policy overhangs ease and investor focus returns to fundamentals, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers to pay $250M milestone payment to SystImmune
- Trump Weekly: Generics to be excluded from pharma tariff plan
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Bristol Myers Squibb Stock (BMY) Slips on $1.5B Orbital Therapeutics Deal
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx